Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer
出版年份 2017 全文链接
标题
Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer
作者
关键词
Hypermethylation, Lung cancer, Bronchial biopsy, Surrogate, Inoperable
出版物
Clinical Epigenetics
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-12-20
DOI
10.1186/s13148-017-0432-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
- (2015) Ji-Youn Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Homeobox A9 directly targeted by miR-196b regulates aggressiveness through nuclear Factor-kappa B activity in non-small cell lung cancer cells
- (2015) Seong-Lan Yu et al. MOLECULAR CARCINOGENESIS
- Epigenetics of lung cancer
- (2015) Scott M. Langevin et al. Translational Research
- The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer
- (2015) Yuling Li et al. Oncotarget
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC
- (2014) Ruo-Chia Tseng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
- (2014) Noemi Reguart et al. LUNG CANCER
- HOXA9inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer
- (2014) Jung-Ah Hwang et al. MOLECULAR CARCINOGENESIS
- A data-driven approach to preprocessing Illumina 450K methylation array data
- (2013) Ruth Pidsley et al. BMC GENOMICS
- Molecular sputum analysis for the diagnosis of lung cancer
- (2013) A J Hubers et al. BRITISH JOURNAL OF CANCER
- Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression
- (2013) I-Ying Kuo et al. INTERNATIONAL JOURNAL OF CANCER
- Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
- (2013) Tien Hoang et al. INVESTIGATIONAL NEW DRUGS
- A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer
- (2012) M. Soda et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients
- (2011) Ji Woong Son et al. CANCER LETTERS
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Quantitative Analysis of Tumor in Bronchial Biopsy Specimens
- (2010) Caroline L. Coghlin et al. Journal of Thoracic Oncology
- Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer
- (2009) De-Yuan Fu et al. BREAST CANCER RESEARCH AND TREATMENT
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started